Možnosti optimalizace léčby pacientů s chronickou myeloidní leukemií
Introduction Patients with chronic myeloid leukemia (CML) are usually treated with imatinib 400 mg/day. Despite excellent therapeutic response to imatinib, 20 - 30 % patients are resistant to this treatment. Several molecular mechanisms leading to imatinib resistance have been proposed (amplificatio...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Doctoral Thesis |
| Language: | Czech |
| Published: |
2016
|
| Online Access: | http://www.nusl.cz/ntk/nusl-351305 |